Get the Stockscreener App
19.28
1.78%
-0.35
After Hours:
19.25
-0.03
-0.16%
Tonix Pharmaceuticals Holding Corp stock is traded at $19.28, with a volume of 410.43K.
It is down -1.78% in the last 24 hours and up +8.80% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$19.63
Open:
$19.7
24h Volume:
410.43K
Relative Volume:
0.48
Market Cap:
$227.05M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-1.7123
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
-1.83%
1M Performance:
+8.80%
6M Performance:
-44.18%
1Y Performance:
-15.77%
1-Day Range:
$19.10
$20.56
1-Week Range:
$18.59
$20.56
52-Week Range:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
19.28 | 231.17M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Equities Analysts Offer Predictions for TNXP FY2025 Earnings - MarketBeat
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel Amid Key Commercialization Phase - citybuzz
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel - citybiz
TNXP: Tonix Now a Commercial Stage Company Following the Launch of Tonmya - Smartkarma
TNXP: Tonix Now a Commercial Stage Company Following the Launch of Tonmya™ - Yahoo Finance
TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals - ts2.tech
Is Tonix Pharmaceuticals Holding Corp. stock ready for breakout - Newser
Tonix receives FDA clearance to launch phase 2 trial for major depressive disorder - Proactive financial news
Is Tonix Pharmaceuticals Holding Corp. stock positioned well for digital economy2025 Buyback Activity & Stepwise Entry and Exit Trade Signals - Newser
Tonix reports positive results in TNX-1500 phase 1 trial - MSN
Tonix Pharmaceuticals (TNXP) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely? - Sahm
Aug Drivers: Why Tonix Pharmaceuticals Holding Corp. stock is trending among retail traders2025 Price Targets & Weekly Watchlist for Hot Stocks - moha.gov.vn
Why analysts remain bullish on Tonix Pharmaceuticals Holding Corp. stockCPI Data & Daily Volume Surge Signals - moha.gov.vn
Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’ - MSN
What drives Tonix Pharmaceuticals Holding Corp stock priceTake Profit Strategies & Free Daily Top Stock Picks for All Investors - earlytimes.in
Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharmaceuticals launches TONMYA, a first-in-class non-opioid Fibromyalgia therapy - Proactive financial news
FDA clears IND for Tonix’s depression treatment candidate By Investing.com - Investing.com Nigeria
Tonix Pharma’s IND Clearance Boosts MDD Treatment Efforts - TipRanks
Tonix Pharmaceuticals (TNXP) Secures FDA Clearance for Depressio - GuruFocus
Tonix To Initiate Phase 2 Trial Of TNX-102 SL For Major Depressive Disorder In Mid-2026 - RTTNews
Tonix Pharmaceuticals gets FDA clearance to develop TNX-102 for depression - Seeking Alpha
Tonix Pharmaceuticals announces FDA IND clearance for phase 2 study of TNX-102 SL - MarketScreener
Tonix Pharmaceuticals Announces FDA Ind Clearance For Phase 2 Study Of Tnx-102 Sl - TradingView
Pharmaceuticals Receives FDA Clearance to Proceed With Phase 2 Study of TNX-102 SL for Major Depressive Disorder - MarketScreener
Tonix Pharmaceuticals (TNXP) Advances with FDA IND Clearance for Depression Treatment - GuruFocus
FDA clears IND for Tonix’s depression treatment candidate - Investing.com India
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder - The Manila Times
Tonix Pharmaceuticals to Advance TNX-102 SL into Pivotal Phase 2 Study for Major Depressive Disorder Following IND Clearance from FDA - Quiver Quantitative
Tonix Pharma (Nasdaq: TNXP) cleared to start Phase 2 HORIZON MDD study of TNX-102 SL - Stock Titan
Tonix Pharmaceuticals increases stock offering capacity to $400 million By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals increases stock offering capacity to $400 million - Investing.com
Tonix Pharma Amends Sales Agreement to Raise Capital - TipRanks
Tonix Pharmaceuticals amends sales agreement with Alliance Global PartnersSEC filing - MarketScreener
Will Tonix Pharmaceuticals Holding Corp. stock split again soonEarnings Recap Report & Expert Approved Momentum Trade Ideas - newser.com
Can Tonix Pharmaceuticals Holding Corp. stock resist market sell offs2025 Big Picture & Long-Term Capital Growth Ideas - newser.com
How Tonix Pharmaceuticals Holding Corp. stock responds to policy changesCEO Change & Short-Term High Return Ideas - newser.com
Risk vs reward if holding onto Tonix Pharmaceuticals Holding Corp.Entry Point & Step-by-Step Swing Trade Plans - newser.com
Will Tonix Pharmaceuticals Holding Corp. stock deliver shareholder valueOil Prices & Consistent Growth Equity Picks - newser.com
Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Tonix Pharma Expands Share Repurchase Program - TipRanks
Tonix Pharmaceuticalsincreases share repurchase program to $35 millionSEC filing - MarketScreener
[8-K] Tonix Pharmaceuticals Holding Corp. Reports Material Event | TNXP SEC FilingForm 8-K - Stock Titan
Tonix Pharmaceuticals Expands Share Repurchase Program - TradingView
Real time alert setup for Tonix Pharmaceuticals Holding Corp. performance2025 Volatility Report & Safe Capital Growth Stock Tips - newser.com
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):